Top Story

Longer course of first-line therapy provided no survival benefit in NSCLC

October 29, 2014

Patients with advanced non–small cell lung cancer treated with six cycles of platinum-based therapy demonstrated no survival advantage compared with those who underwent three or four cycles of therapy, according to results of a systematic review and meta-analysis.

Although platinum-based chemotherapy is the standard first-line treatment for patients with advanced NSCLC, the optimal number of treatment cycles has not been established, according to background information in the study.

figure FDA News

FDA grants breakthrough therapy designation to Keytruda for NSCLC

October 27, 2014
The FDA has issued breakthrough therapy designation to pembrolizumab for treating patients with epidermal growth factor receptor mutation-negative and anaplastic…
figure Meeting News Coverage

Targeted treatments for lung cancer likely to drive field forward

October 17, 2014
WASHINGTON — Recent progress in the use of genomics to treat lung cancer is likely to advance the field of cancer treatment, according to Mark G. Kris, MD
In the Journals

Medicare reimbursement policy failed to significantly reduce chemotherapy cost

October 16, 2014
The Medicare Prescription Drug, Improvement and Modernization Act of 2003, intended to slow the skyrocketing costs of drugs the federal government must pay for to treat…
CME
figure

New Advances, New Options: Evaluating the Changing Landscape of Hemophilia to Optimize Patient Outcomes

This activity is supported by an educational grant from Biogen Idec.

The bleeding abnormalities associated with hemophilia can have devastating consequences for patients. Recent advances…
More »
CME CNE
figure

Treatment Decision-Making through the Spectrum of MDS: Case 2 High Risk MDS

An educational presentation from Aplastic Anemia & MDS International Foundation.

MDS is a difficult disease to diagnose and treat. Frequently it is challenging for healthcare providers to explain to…
More »

Filter By:

In the Journals

Longer course of first-line therapy provided no survival benefit in NSCLC

October 29, 2014
Patients with advanced non–small cell lung cancer treated with six cycles of platinum-based therapy demonstrated no survival advantage compared…
figure FDA News

FDA grants breakthrough therapy designation to Keytruda for NSCLC

October 27, 2014
The FDA has issued breakthrough therapy designation to pembrolizumab for treating patients with epidermal growth factor receptor mutation-negative…
figure Meeting News Coverage

Targeted treatments for lung cancer likely to drive field forward

October 17, 2014
WASHINGTON — Recent progress in the use of genomics to treat lung cancer is likely to advance the field of cancer treatment, according to…
In the Journals

Medicare reimbursement policy failed to significantly reduce chemotherapy cost

October 16, 2014
The Medicare Prescription Drug, Improvement and Modernization Act of 2003, intended to slow the skyrocketing costs of drugs the federal government…
Meeting News Coverage Perspective

Physician tumor board participation linked to clinical trial enrollment

October 14, 2014
Patients with lung or colorectal cancers whose physicians attended weekly multidisciplinary tumor board meetings were more likely to enroll in…
In the Journals

ASCO: Offer EGFR, ALK testing to all patients with lung adenocarcinoma

October 13, 2014
ASCO today endorsed a joint clinical practice guideline from three other entities that addresses questions about the appropriate use of…
In the Journals

E-cigarettes unhelpful for smoking cessation among patients with cancer

October 13, 2014
A study of patients with cancer who smoke showed those who used electronic cigarettes were more nicotine-dependent than nonusers.Those who used…
Institution Notes

UPCI appoints co-director of lung cancer program

October 12, 2014
James Herman, MD, has been named co-leader of the University of Pittsburgh Cancer Institute’s lung cancer program.Herman, a leader in the…
Institution Notes

Meridian appoints medical director for thoracic oncology

October 7, 2014
Meridian Cancer Care appointed Thomas Lee Bauer II, MD, as its medical director for thoracic oncology.Bauer will be based at Jersey Shore University…
figure In the Journals

Two novel mutations linked to ALK inhibitor resistance in NSCLC

October 7, 2014
Two novel ALK mutations, V1180L and I1171T, were associated with resistance to crizotinib and alectinib but were sensitive to other next-generation…
More Headlines »